Novoprost (Suppositories) Instructions for Use
Marketing Authorization Holder
Novoprost, LLC (Russia)
Manufactured By
Tula Pharmaceutical Factory, LLC (Russia)
ATC Code
G04BX (Other drugs for the treatment of urological diseases)
Active Substance
Prostate extract (Grouping name)
Dosage Form
| Novoprost | Rectal suppositories 10 mg: 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Rectal suppositories from white to white with a yellowish or grayish-brownish tint, torpedo-shaped; the appearance of a white coating on the surface of the suppository and the presence of an air rod and a funnel-shaped depression on the cut are allowed.
| 1 supp. | |
| Prostate extract (calculated as water-soluble peptides) | 10 mg |
Excipients: hard fat (Witepsol brand H15, Suppocire brand NA15) – 0.6 g, hard fat (Witepsol brand W35, Suppocire brand NAS50) – sufficient quantity to obtain a suppository weighing 1.25 g.
5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.
Clinical-Pharmacological Group
Drug used for diseases of the prostate gland
Pharmacotherapeutic Group
Drugs used in urology; other drugs used in urology
Pharmacological Action
A drug of animal origin. It has an organotropic effect on the prostate gland.
It reduces the degree of edema and leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secretion of acini, and stimulates the muscle tone of the bladder.
It reduces thrombus formation, has antiplatelet activity, and prevents the development of venule thrombosis in the prostate gland.
It normalizes the parameters of the prostate gland and ejaculate.
Pharmacokinetics
As a peptide substance, it is broken down by cellular proteases into amino acids. It does not have a cumulative effect.
Indications
Chronic prostatitis; benign prostatic hyperplasia; conditions before and after surgical interventions on the prostate gland.
ICD codes
| ICD-10 code | Indication |
| N40 | Hyperplasia of prostate |
| N41 | Inflammatory diseases of prostate |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| Z98.8 | Other specified postprocedural states |
| ICD-11 code | Indication |
| GA90 | Hyperplasia of prostate |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| QB6Z | Surgical or postprocedural conditions, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
This medication is for adult men only. Use rectally. The standard dose is one 10 mg suppository administered twice daily.
Insert the suppository deeply into the rectum after bowel evacuation. Follow a consistent schedule, typically in the morning and evening.
The standard treatment course is 10 days. A second course may be administered if clinically indicated, following a consultation with a physician.
For pre-operative and post-operative preparation for prostate surgery, use one suppository twice daily for 3-5 days before the scheduled intervention and for 10-14 days after surgery, as directed.
Before initiating treatment for benign prostatic hyperplasia, confirm the benign nature of the condition. Perform standard monitoring for this disease regularly during therapy.
Before and during treatment for chronic prostatitis, analyze prostate secretion as recommended by a physician.
Discontinue use and seek medical advice if severe local irritation or signs of an allergic reaction occur.
Adverse Reactions
Allergic reactions very rarely – urticaria.
Contraindications
Hypersensitivity to the active substance; age under 18 years.
Use in Pregnancy and Lactation
Not applicable.
Pediatric Use
Contraindicated for use under 18 years of age.
Special Precautions
Before starting treatment for chronic prostatitis and, if necessary, during treatment, it is recommended to perform an analysis of the prostate secretion.
During the use of the drug for the treatment of benign prostatic hyperplasia, standard monitoring of this disease should be regularly performed. Before starting treatment, it is necessary to ensure that the pathology is benign.
Drug Interactions
Compatible with antibacterial drugs used to treat prostatitis.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Noopept, pills 10mg, 50pcs
No-spa pills 40mg, 64pcs
Kagocel pills 12mg, 30pcs
Fenotropil pills 100mg, 60pcs
Picamilon pills 50mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Nootropil pills 800mg, 30pcs
Phenibut-Vertex pills 250mg, 20pcs
Mildronate capsules 500mg, 90pcs
Belosalic, ointment, 30g
Belosalic, lotion solution for external use spray 100ml
Daivobet, ointment, 30g
Ingavirin capsules 90mg, 10pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs 